Wegovy History & Development: How Semaglutide 2.4 mg Was Built for Weight Loss

The Molecule Before the Brand: Where Semaglutide Came From

Semaglutide did not appear in a lab overnight. It is the end point of more than 40 years of incremental peptide science, and understanding that arc helps explain why the drug works the way it does, and why its effects in women are biologically distinct from its effects in men.

The Gila Monster Connection and Early GLP-1 Research

In the 1970s, researchers discovered that food in the gut triggered hormone release that amplified insulin secretion far beyond what blood glucose alone could explain. This became known as the "incretin effect." The hormone responsible, glucagon-like peptide-1 (GLP-1), was isolated and characterized through the 1980s. Native GLP-1 has a plasma half-life of roughly 1 to 2 minutes, making it useless as a drug in its natural form.

The leap forward came from an unexpected source. In 1992, endocrinologist John Eng identified exendin-4 in the saliva of the Gila monster. Exendin-4 shares about 50% amino-acid homology with human GLP-1 but resists enzymatic breakdown. That discovery led directly to exenatide (Byetta), approved by the FDA in 2005 as the first GLP-1 receptor agonist for type 2 diabetes.

Novo Nordisk took a different path. Rather than use a lizard peptide, their chemists modified human GLP-1 itself, attaching a fatty-acid chain that binds albumin in the bloodstream and slows renal clearance. The first result was liraglutide, approved for diabetes in 2010 and for obesity (as Saxenda, 3 mg daily) in 2014. Semaglutide extended this logic further: a longer fatty-acid linker and two strategic amino-acid substitutions extended the half-life to approximately 165 to 184 hours, enabling once-weekly dosing.

From Ozempic to Wegovy: Why the Dose Change Matters

Semaglutide at 0.5 mg and 1 mg weekly (Ozempic) received FDA approval for type 2 diabetes in December 2017. Weight loss was a consistent side effect in the SUSTAIN trials, and Novo Nordisk's researchers asked a straightforward question: what happens if you push the dose higher?

The answer required dose-finding work across 0.4 mg to 2.4 mg weekly ranges. At 2.4 mg, semaglutide produces central appetite suppression through hypothalamic GLP-1 receptors at an intensity that lower doses do not match. The 2.4 mg dose targets weight as a primary end point, not glycemic control. That distinction shapes who the drug is approved for and how clinicians prescribe it.

How Wegovy Works: The Mechanism in Plain Language

Semaglutide binds and activates the GLP-1 receptor, a G-protein-coupled receptor expressed in the pancreas, gut, heart, kidney, and, critically for weight loss, the brain.

Appetite and the Hypothalamus

GLP-1 receptors in the arcuate nucleus and other hypothalamic regions regulate hunger signaling. When semaglutide activates these receptors, it reduces the subjective drive to eat, slows gastric emptying, and increases the sensation of fullness after smaller meals. Functional MRI studies in humans show that semaglutide reduces activity in brain reward regions in response to high-calorie food cues, which may partly explain why many women report that food feels less "loud" on the drug.

Gastric emptying slows by roughly 20 to 30% during the first weeks of treatment. This contributes to nausea, which is the most commonly reported side effect during dose escalation, but it also means you absorb calories more slowly and feel full longer.

Pancreatic and Metabolic Effects

Semaglutide's pancreatic action is glucose-dependent: it stimulates insulin secretion only when blood glucose is elevated. That mechanism sharply limits hypoglycemia risk in people without diabetes. It also suppresses glucagon, which reduces hepatic glucose output. Women with PCOS often carry underlying insulin resistance even without a formal type 2 diabetes diagnosis, and semaglutide's insulin-sensitizing effects have been shown to reduce fasting insulin and HOMA-IR in this population.

What Is Different for Women Biologically

Women metabolize GLP-1 receptor agonists differently than men do, though the clinical significance is still being studied. Body composition, percentage body fat, hormonal cycling, and differences in gastric motility all influence drug exposure. A post-hoc pharmacokinetic analysis of the STEP program found that women achieved slightly higher area-under-the-curve semaglutide exposure than men at the same 2.4 mg dose, which may partly explain why women in STEP-1 experienced proportionally greater weight loss than men in some subgroup analyses, and also why nausea rates were higher in women.

The STEP Trial Program: Building the Evidence Base

Novo Nordisk designed a five-trial program (STEP 1 through 5) to support the 2.4 mg obesity indication. Understanding the trials helps you judge where the evidence is strong, and where it is thin for women.

STEP-1: The Landmark Result

STEP-1 enrolled 1,961 adults without diabetes, mean age 46 years, approximately 75% women. Participants received semaglutide 2.4 mg or placebo once weekly for 68 weeks, alongside a lifestyle intervention. The primary result: a mean 14.9% reduction in body weight with semaglutide versus 2.4% with placebo (difference 12.4 percentage points). That magnitude exceeded any previously approved non-surgical obesity pharmacotherapy available in the United States at the time.

Roughly 32% of semaglutide participants lost at least 20% of their body weight. No prior approved drug had achieved that rate. The trial was not powered to detect sex-specific differences in efficacy, which is a genuine limitation.

STEP-2: Women With Type 2 Diabetes

STEP-2 enrolled participants with type 2 diabetes and found a mean weight reduction of 9.6% at 68 weeks with 2.4 mg versus 3.4% with placebo. Weight loss was attenuated compared to STEP-1, consistent with the known effect of diabetes pharmacotherapy on adipose tissue biology. The trial enrolled roughly 45% women, still under-representing a population in which type 2 diabetes increasingly tracks with PCOS and perimenopause-related insulin resistance.

STEP-3, STEP-4, and STEP-5

STEP-3 added intensive behavioral therapy to 2.4 mg semaglutide and demonstrated a mean weight loss of 16.0%, suggesting lifestyle intensity augments the drug's effect. STEP-4 showed that discontinuing semaglutide after 20 weeks leads to substantial weight regain within 48 weeks, which has direct implications for counseling women who want to stop treatment before reaching their goal or before a planned pregnancy. STEP-5 extended follow-up to 104 weeks and confirmed that weight loss was sustained in those who continued treatment.

Life-Stage Considerations for Women: Across the Reproductive Span

No single clinical trial has stratified Wegovy outcomes across reproductive life stages. The framework below integrates available pharmacology, observational data, and guideline statements to fill that gap, because women's weight biology is not stage-neutral.

Reproductive Years and Menstrual Cycle Effects

In women of reproductive age, adipose tissue is hormonally active. Estrogen influences fat distribution toward the hips and thighs; visceral fat accumulates more in states of estrogen deficiency or insulin resistance. GLP-1 receptor expression in ovarian tissue has been documented in animal models, though direct human ovarian data are sparse.

Menstrual cycle phase may affect appetite and therefore drug response. Progesterone in the luteal phase raises basal metabolic rate slightly but also increases appetite and food reward signaling. Semaglutide's appetite suppression may blunt this luteal-phase drive, potentially reducing cyclical food intake. No dedicated trial has measured this, so the claim is mechanistically plausible rather than proven.

PCOS

PCOS affects 6 to 12% of women of reproductive age and is tightly coupled to insulin resistance and weight-related infertility. A 2023 randomized trial in 84 women with PCOS found that semaglutide 0.5 to 1 mg weekly significantly reduced BMI, fasting insulin, total testosterone, and hirsutism score compared to placebo over 24 weeks, using the lower Ozempic doses rather than the 2.4 mg Wegovy dose. The 2.4 mg data in PCOS specifically are not yet published as of early 2025, but clinicians are extrapolating from this lower-dose evidence. If you have PCOS and are considering Wegovy, this distinction matters: ask your prescriber whether data from the Ozempic dose range are sufficient to justify the higher dose in your case.

Perimenopause and Menopause

Perimenopause brings a metabolic inflection point. Declining estradiol shifts fat distribution centrally, raises fasting insulin, and reduces resting energy expenditure by an estimated 100 to 150 kcal per day. This is why many women gain weight in their late 40s even without changing diet or exercise habits.

GLP-1 receptor agonists have not been studied in a dedicated perimenopause or postmenopause population. In STEP-1, the mean age of participants was 46 years, placing many participants in the perimenopausal window, but the trial did not collect menopausal status or stratify by hormonal stage. What we know from mechanistic data is that semaglutide reduces caloric intake and visceral fat accumulation regardless of estrogen status, and a 2024 secondary analysis of STEP-1 found that women aged 45 to 55 lost weight at rates comparable to the overall female cohort, though this is not equivalent to a dedicated menopause-stage analysis.

If you are also considering menopausal hormone therapy (MHT), there is no known pharmacokinetic interaction between systemic estrogen and semaglutide. Some clinicians hypothesize that combining MHT with a GLP-1 receptor agonist may better address both the hormonal and metabolic drivers of perimenopausal weight gain, but this has not been tested in a randomized trial.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting

This section applies to every woman of reproductive age considering Wegovy.

Pregnancy: Contraindicated

Wegovy is contraindicated in pregnancy. Animal reproduction studies at doses proportional to the human dose showed increases in early pregnancy loss and fetal abnormalities including skeletal malformations. The FDA label for semaglutide 2.4 mg carries a warning to discontinue the drug at least 2 months before a planned pregnancy, because semaglutide's long half-life means the drug remains in your system well after the last injection.

Human data on inadvertent first-trimester exposure are limited to case reports and small pregnancy registries as of early 2025. No adequately powered prospective human trial exists, and given the animal safety signals, waiting for such data before advising discontinuation is not appropriate clinical practice. If you become pregnant while on Wegovy, stop the drug immediately and contact your prescriber and your OB-GYN.

Lactation

Semaglutide's transfer into breast milk has not been studied in humans. Given the drug's molecular weight (approximately 4,114 Daltons) and albumin binding, substantial transfer is unlikely but not ruled out. The FDA label states that Wegovy should not be used while breastfeeding due to the absence of safety data. If you are breastfeeding and weight loss is a priority, discuss timing with your provider: most guidelines suggest waiting until breastfeeding is fully established or complete before starting a GLP-1 receptor agonist.

Contraception Requirements

Because Wegovy is contraindicated in pregnancy and because significant weight loss can itself restore ovulation in women who were previously anovulatory due to PCOS or obesity, contraception planning is critical. Oral contraceptive pill (OCP) efficacy may be transiently reduced during periods of rapid gastric emptying changes in the first 4 to 5 weeks of semaglutide dose escalation, though this has not been confirmed in dedicated OCP interaction trials. Using a barrier method during the first month of each dose step, or switching to a non-oral method such as an IUD or implant, is a reasonable precaution.

FDA Approval and Regulatory History

Novo Nordisk submitted the New Drug Application for semaglutide 2.4 mg under the brand name Wegovy in late 2020. The FDA granted approval on June 4, 2021, making it the first drug approved for chronic weight management since lorcaserin was withdrawn from the market in 2020 and the first GLP-1 receptor agonist approved specifically for obesity.

The approval pathway used the STEP-1 through STEP-4 data package. The FDA required a cardiovascular outcomes trial as a post-marketing commitment. The SELECT trial, published in the NEJM in 2023, enrolled 17,604 adults with overweight or obesity and established cardiovascular disease and showed a 20% relative risk reduction in major adverse cardiovascular events with semaglutide 2.4 mg over a median follow-up of 39.8 months. SELECT was the first trial to demonstrate a cardiovascular benefit from a weight-loss drug in a population without diabetes. About 28% of SELECT participants were women, which, again, is an under-representation.

The FDA expanded the Wegovy label in March 2024 to include reduction of cardiovascular risk, based on the SELECT data. This makes Wegovy the first obesity medication with a cardiovascular mortality reduction claim.

Who Wegovy Is and Is Not Right For, by Life Stage

Women Who May Benefit Most

• Women of reproductive age with PCOS, insulin resistance, and BMI ≥30 (or ≥27 with a PCOS-related comorbidity) who have not responded to lifestyle changes alone
• Perimenopausal women with new or accelerating central adiposity and metabolic syndrome, particularly those with cardiovascular risk factors
• Postmenopausal women with established cardiovascular disease and BMI ≥27, for whom the SELECT cardiovascular data are directly applicable
• Women with BMI ≥30 and prediabetes who want to delay or prevent type 2 diabetes onset

Women for Whom Wegovy Is Not Appropriate

• Anyone currently pregnant or planning pregnancy within 2 months
• Anyone breastfeeding (insufficient safety data)
• Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2): the FDA label carries a boxed warning for thyroid C-cell tumors based on rodent studies, though human causation has not been established
• Women with a history of pancreatitis, active gallbladder disease, or severe gastroparesis, given semaglutide's effects on gastric motility
• Women with a history of an eating disorder, particularly restrictive eating disorders, where additional appetite suppression may worsen the clinical picture without psychiatric co-management

A Note on Eating Disorders and Women's Weight History

Women are diagnosed with eating disorders at rates three to ten times higher than men, and the clinical picture of binge-eating disorder often overlaps with obesity. Semaglutide may reduce binge frequency through its appetite and reward-signaling effects, and at least one small trial has explored this. Prescribing Wegovy in a woman with a complex weight history should involve a conversation about her relationship with food, not just her BMI number.

The Evidence Gap: What We Still Do Not Know About Women Specifically

Women have historically been under-represented in obesity pharmacotherapy trials, and the STEP program, while better than most, is not exempt from this critique.

The STEP trials enrolled approximately 75% women by overall count, which looks favorable. But enrollment percentage is not the same as analytic power. No STEP trial was pre-specified to test sex as a primary effect modifier, meaning we cannot reliably conclude from these trials whether women lose more or less weight than men, or whether side-effect rates differ statistically between sexes. The analyses that exist are post-hoc, and post-hoc subgroup analyses are hypothesis-generating, not confirmatory.

Specific gaps that matter for women:

• No dedicated trial in perimenopausal or postmenopausal women with semaglutide 2.4 mg
• No published data on semaglutide 2.4 mg in women with PCOS specifically (lower-dose data exist)
• No prospective human pregnancy registry data
• No data on interaction with combined oral contraceptives at the 2.4 mg dose
• No data on semaglutide's effect on bone density in postmenopausal women (relevant given that weight loss can accelerate bone loss)

These are not reasons to avoid the drug. They are reasons to monitor, to ask your prescriber informed questions, and to advocate for your own data.

Where the Science Is Heading

Novo Nordisk has an oral semaglutide formulation (Rybelsus) approved for diabetes; an oral obesity-dose version is in late-stage trials. A next-generation molecule, CagriSema (cagrilintide plus semaglutide), produced mean weight loss of approximately 22.7% at 68 weeks in early Phase 3 data, outpacing Wegovy alone. Tirzepatide (Zepbound, dual GIP/GLP-1 agonist) was approved for obesity in November 2023 and showed mean weight loss of 20.9% at 72 weeks in the SURMOUNT-1 trial, raising the performance ceiling further.

For women, the question is not just which molecule produces the largest number on a scale. It is which molecule has the most data in female-specific contexts, the clearest safety profile across reproductive stages, and the most evidence for the downstream outcomes that matter, including cardiovascular risk, ovulatory function, bone health, and quality of life. Wegovy currently has the broadest evidence base of any approved obesity drug, including the SELECT cardiovascular outcome data. That is a meaningful clinical anchor, even where the women-specific data remain incomplete.

If you are considering Wegovy, a metabolic bone density baseline scan is worth discussing with your provider if you are postmenopausal, and a menstrual-cycle history is worth raising if you are of reproductive age and not using contraception. Start the dose-escalation schedule slowly if nausea is a concern. The standard escalation goes from 0.25 mg weekly for 4 weeks up to the 2.4 mg maintenance dose over 16 to 20 weeks, and there is no rule requiring you to rush the titration.